Entrectinib resistance mechanisms in ROS1-rearranged non-small cell lung cancer

Bo Mi Ku(Samsung Medical Center), Myung‐Ju Ahn(Sungkyunkwan University)

Investigational New Drugs

May 24, 2019

10.1007/s10637-019-00795-3

Cited by 50

Related Papers

Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer

|New England Journal of Medicine|2013|3.4k

Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial

|The Lancet|2019|3.3k

Osimertinib or Platinum–Pemetrexed in <i>EGFR</i> T790M–Positive Lung Cancer

|New England Journal of Medicine|2016|3.3k

Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study

|The Lancet|2018|1.7k

Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1–2 trials

|The Lancet Oncology|2019|537